secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2022-12-21T23:59:59+00:00
Accession:  0001851734-22-000740
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen to acquire Pherin for ~12.4M shares, gaining full IP rights to PH94B and PH10
--------------------------------------------------------------------------------

- Vistagen will issue ~12.4M shares of common stock and a nominal cash payment (under $50k) to acquire Pherin.
- Acquisition eliminates all future royalty and milestone payment obligations related to PH94B and PH10.
- Pipeline expands with three new pherine candidates: PH15 (cognition), PH80 (migraine/hot flashes), PH284 (appetite disorders).
- PH94B in Phase 3 for social anxiety disorder and Phase 2 for adjustment disorder with anxiety; PH10 in development for major depressive disorder.
- Closing subject to Pherin stockholder approval and other customary conditions; lock-up of 180 days for certain Pherin holders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000185173422000740/0001851734-22-000740-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000185173422000740/vtgn20221220_8k.htm
  HTML page:      https://secwatch.observer/filing/0001851734-22-000740

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer